Some staff members at the Food and Drug Administration (FDA) are considering leaving amidst rumors that Robert F. Kennedy Jr. may be appointed to a health role in the incoming Trump administration. Staff turnover is common during a new administration, and concerns about potential changes were raised before Trump’s first term, but there was minimal turnover. Now, with the added anxiety over Kennedy’s possible appointment, more staff are considering their options. It’s unclear what role Kennedy may have, but he has expressed a desire to shake up federal health agencies, including the FDA.
FDA Commissioner Robert Califf expressed uncertainty about the agency’s future following the election results. Employees are uncertain about potential changes in leadership and policies, including Trump’s suggestion of ending the revolving door between government and lobbying positions. Some staffers may see retirement as an opportune time to leave amidst the uncertainty. It is possible that Kennedy may not have significant influence over the FDA, despite his potential appointment to a health role.
The FDA did not respond to requests for comment on the potential staff turnover. Some employees are monitoring the situation and waiting to see how things unfold, as the future direction of the agency remains uncertain. The concerns about changes in leadership, policies, and potential restrictions on future job prospects have led to speculation and anxiety among FDA employees.
Photo credit
www.nbcnews.com
